{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T20:15:09Z","timestamp":1788552909456,"version":"build-2803163510"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"EuBiologics Co. Ltd"},{"name":"EuBiologics Co., Ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    A randomized, active-controlled, double-blind, first-in-human, phase 1 study was conducted in healthy Korean adults to evaluate the safety, tolerability, and immunogenicity of EuNmCV-5, a new pentavalent meningococcal vaccine targeting serogroups A, C, W, X, and Y. Sixty participants randomly received a single dose of either EuNmCV-5 or MenACWY-CRM, a quadrivalent vaccine containing serogroups A, C, W, and Y. Safety was assessed through monitoring anaphylactic reactions, adverse events for 28 days, and serious adverse events over 180 days. Immunogenicity was assessed via rabbit complement-dependent serum bactericidal antibody (rSBA) assay. EuNmCV-5 was safe, well-tolerated, and elicited a substantial antibody titer increase. The seroprotection rates exceeded 96.7%, and the seroconversion rates were over 85% for all the targeted serogroups. It showed higher seroconversion rates against serogroups A and C (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.0016 and 0.0237, respectively) and elicited a substantial increase in GMT for all targeted serogroups compared to the MenACWY-CRM.\n                  <\/jats:p>\n                  <jats:p>ClinicalTrials.gov identifier: NCT05739292.<\/jats:p>","DOI":"10.1038\/s41541-024-00935-8","type":"journal-article","created":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T03:02:34Z","timestamp":1722999754000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["A randomized study to evaluate the safety and immunogenicity of a pentavalent meningococcal vaccine"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-2141-2407","authenticated-orcid":false,"given":"Yoonjin","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sungyeun","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Sang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SeungHwan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chankyu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinil","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Her","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaeseong","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,7]]},"reference":[{"key":"935_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-61779-346-2_1","volume":"799","author":"NG Rouphael","year":"2012","unstructured":"Rouphael, N. G. & Stephens, D. S. Neisseria meningitidis: biology, microbiology, and epidemiology. Methods Mol. Biol. 799, 1\u201320 (2012).","journal-title":"Methods Mol. Biol."},{"key":"935_CR2","doi-asserted-by":"publisher","first-page":"2172922","DOI":"10.1080\/21645515.2023.2172922","volume":"19","author":"PN Nguyen","year":"2023","unstructured":"Nguyen, P. N., Hung, N. T., Mathur, G., Pinto, T. J. P. & Minh, N. H. L. Review of the epidemiology, diagnosis and management of invasive meningococcal disease in Vietnam. Hum. Vaccin Immunother. 19, 2172922 (2023).","journal-title":"Hum. Vaccin Immunother."},{"key":"935_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-7-47","volume":"7","author":"M Ramakrishnan","year":"2009","unstructured":"Ramakrishnan, M. et al. Sequelae due to bacterial meningitis among African children: a systematic literature review. BMC Med. 7, 47 (2009).","journal-title":"BMC Med."},{"key":"935_CR4","unstructured":"World Health Organization. Meningococcal vaccines: WHO position paper, November 2011. Wkly Epidemiol Rec. 86, 521\u2013539 (2011)."},{"key":"935_CR5","unstructured":"Centers for Disease Control and Prevention (2023) Meningococcal Disease. In CDC Yellow Book: Health Information for International Travel 2024, Oxford University Press, accessed on May 2024; https:\/\/wwwnc.cdc.gov\/travel\/yellowbook\/2024\/infections-diseases\/meningococcal-disease."},{"key":"935_CR6","unstructured":"World Health Organization (2024) Weekly Epidemiological Record. 99, 1\u201310, accessed on May 2024; https:\/\/www.who.int\/publications\/journals\/weekly-epidemiological-record."},{"key":"935_CR7","unstructured":"World Health Organization (2023) Weekly Epidemiological Record. 98(39), 453\u2013470, accessed on May 2024; https:\/\/www.who.int\/publications\/journals\/weekly-epidemiological-record."},{"key":"935_CR8","doi-asserted-by":"publisher","unstructured":"Bolgiano, B. et al. Evaluation of critical quality attributes of a pentavalent (A, C, Y, W, X) meningococcal conjugate vaccine for global use. Pathogens 10 https:\/\/doi.org\/10.3390\/pathogens10080928 (2021).","DOI":"10.3390\/pathogens10080928"},{"key":"935_CR9","doi-asserted-by":"publisher","first-page":"2852","DOI":"10.1016\/j.vaccine.2013.04.036","volume":"31","author":"O Xie","year":"2013","unstructured":"Xie, O., Pollard, A. J., Mueller, J. E. & Norheim, G. Emergence of serogroup X meningococcal disease in Africa: need for a vaccine. Vaccine 31, 2852\u20132861 (2013).","journal-title":"Vaccine"},{"key":"935_CR10","unstructured":"A new vaccine will change the balance of the fight against meningitis, <https:\/\/www.who.int\/news-room\/feature-stories\/detail\/a-new-vaccine-will-change-the-balance-of-the-fight-against-meningitis> (2023)."},{"key":"935_CR11","unstructured":"World Health Organization. WHO Expert Committee on Biological Standardization, Vol. 27 (World Health Organization, 1976)."},{"key":"935_CR12","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","volume":"23","author":"R Borrow","year":"2005","unstructured":"Borrow, R., Balmer, P. & Miller, E. Meningococcal surrogates of protection-serum bactericidal antibody activity. Vaccine 23, 2222\u20132227 (2005).","journal-title":"Vaccine"},{"key":"935_CR13","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/S1473-3099(18)30400-6","volume":"18","author":"WH Chen","year":"2018","unstructured":"Chen, W. H. et al. Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine containing serogroups A, C, Y, W, and X in healthy adults: a phase 1, single-centre, double-blind, randomised, controlled study. Lancet Infect. Dis. 18, 1088\u20131096 (2018).","journal-title":"Lancet Infect. Dis."},{"key":"935_CR14","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1016\/j.vaccine.2015.07.019","volume":"33","author":"ED McIntosh","year":"2015","unstructured":"McIntosh, E. D., Broker, M., Wassil, J., Welsch, J. A. & Borrow, R. Serum bactericidal antibody assays\u2014the role of complement in infection and immunity. Vaccine 33, 4414\u20134421 (2015).","journal-title":"Vaccine"},{"key":"935_CR15","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1056\/NEJMoa2214924","volume":"388","author":"FC Haidara","year":"2023","unstructured":"Haidara, F. C. et al. Meningococcal ACWYX conjugate vaccine in 2-to-29-year-olds in Mali and Gambia. N. Engl. J. Med. 388, 1942\u20131955 (2023).","journal-title":"N. Engl. J. Med."},{"key":"935_CR16","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1056\/NEJMoa2013615","volume":"384","author":"MD Tapia","year":"2021","unstructured":"Tapia, M. D. et al. Meningococcal serogroup ACWYX conjugate vaccine in Malian toddlers. N. Engl. J. Med. 384, 2115\u20132123 (2021).","journal-title":"N. Engl. J. Med."},{"key":"935_CR17","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ijid.2016.02.010","volume":"45","author":"DS Kim","year":"2016","unstructured":"Kim, D. S. et al. Safety and immunogenicity of a single dose of a quadrivalent meningococcal conjugate vaccine (MenACYW-D): a multicenter, blind-observer, randomized, phase III clinical trial in the Republic of Korea. Int. J. Infect. Dis. 45, 59\u201364 (2016).","journal-title":"Int. J. Infect. Dis."},{"key":"935_CR18","doi-asserted-by":"publisher","first-page":"e169","DOI":"10.3346\/jkms.2019.34.e169","volume":"34","author":"HW Kim","year":"2019","unstructured":"Kim, H. W., Lee, S., Lee, J. H., Woo, S. Y. & Kim, K. H. Comparison of immune responses to two quadrivalent meningococcal conjugate vaccines (CRM197 and diphtheria toxoid) in healthy adults. J. Korean Med. Sci. 34, e169 (2019).","journal-title":"J. Korean Med. Sci."},{"key":"935_CR19","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1128\/CVI.00207-09","volume":"16","author":"KS Reisinger","year":"2009","unstructured":"Reisinger, K. S. et al. Quadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, Menactra. Clin. Vaccin. Immunol. 16, 1810\u20131815 (2009).","journal-title":"Clin. Vaccin. Immunol."},{"key":"935_CR20","unstructured":"MENVEO[package insert]. Brentford, United Kingdom: GlaxoSmithKline. https:\/\/www.fda.gov\/media\/78514\/download Revised October 2022. Accessed on May 2024."},{"key":"935_CR21","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1128\/cdli.4.2.156-167.1997","volume":"4","author":"SE Maslanka","year":"1997","unstructured":"Maslanka, S. E. et al. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group. Clin. Diagn. Lab. Immunol. 4, 156\u2013167 (1997).","journal-title":"Clin. Diagn. Lab. Immunol."}],"updated-by":[{"DOI":"10.1038\/s41541-024-00965-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000}}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-00935-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-00935-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-00935-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T10:04:09Z","timestamp":1726740249000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-00935-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,7]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["935"],"URL":"https:\/\/doi.org\/10.1038\/s41541-024-00935-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4003648\/v1","asserted-by":"object"}]},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,7]]},"assertion":[{"value":"1 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.K.L., J.I.K., and H.H. are full-time employees of EuBiologics Co., Ltd., Seoul, Republic of Korea, but declare no non-financial competing interests. All other authors declare no competing financial or non-financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"140"}}